{"id": "article-23786_0", "title": "Isoniazid -- Continuing Education Activity", "content": "Isoniazid (INH) is an antibiotic indicated in the first-line treatment of active Mycobacterium tuberculosis (TB) infection. INH has been\u00a0a significant drug in TB treatment regimens for decades. INH functions as a prodrug activated by the catalase-peroxidase KatG, generating various radicals and adducts that inhibit the production of mycolic acids, the essential components of the mycobacterium's cell wall. This mechanism of action makes INH a potent bactericidal agent. Moreover, INH exhibits synergistic effects with other species generated by KatG and other medications utilized in TB treatment.", "contents": "Isoniazid -- Continuing Education Activity. Isoniazid (INH) is an antibiotic indicated in the first-line treatment of active Mycobacterium tuberculosis (TB) infection. INH has been\u00a0a significant drug in TB treatment regimens for decades. INH functions as a prodrug activated by the catalase-peroxidase KatG, generating various radicals and adducts that inhibit the production of mycolic acids, the essential components of the mycobacterium's cell wall. This mechanism of action makes INH a potent bactericidal agent. Moreover, INH exhibits synergistic effects with other species generated by KatG and other medications utilized in TB treatment."}
{"id": "article-23786_1", "title": "Isoniazid -- Continuing Education Activity", "content": "Mutations in the katG , inhA , kasA , and ahpC genes can lead to resistance against INH therapy. Resistance of M tuberculosis can occur more rapidly with INH monotherapy. This\u00a0activity reviews the indications, mechanism of action, and contraindications of INH as a valuable agent in treating both active and latent\u00a0TB infections. This activity also highlights the drug's adverse event profile, regimens and dosing, and other key factors pertinent to the interprofessional healthcare team when using\u00a0INH for TB treatment.", "contents": "Isoniazid -- Continuing Education Activity. Mutations in the katG , inhA , kasA , and ahpC genes can lead to resistance against INH therapy. Resistance of M tuberculosis can occur more rapidly with INH monotherapy. This\u00a0activity reviews the indications, mechanism of action, and contraindications of INH as a valuable agent in treating both active and latent\u00a0TB infections. This activity also highlights the drug's adverse event profile, regimens and dosing, and other key factors pertinent to the interprofessional healthcare team when using\u00a0INH for TB treatment."}
{"id": "article-23786_2", "title": "Isoniazid -- Continuing Education Activity", "content": "Objectives: Identify patients with active or latent tuberculosis who can benefit from isoniazid (INH) treatment based on clinical guidelines and risk factors. Screen patients for risk factors predisposing them to adverse reactions or interactions with isoniazid (INH), considering comorbidities and concomitant medications. Apply knowledge of isoniazid's (INH's) mechanism of action and pharmacokinetics to optimize dosing and minimize the risk of resistance. Collaborate with other healthcare professionals to coordinate comprehensive tuberculosis management, including monitoring for adverse effects, drug interactions, and treatment outcomes. Access free multiple choice questions on this topic.", "contents": "Isoniazid -- Continuing Education Activity. Objectives: Identify patients with active or latent tuberculosis who can benefit from isoniazid (INH) treatment based on clinical guidelines and risk factors. Screen patients for risk factors predisposing them to adverse reactions or interactions with isoniazid (INH), considering comorbidities and concomitant medications. Apply knowledge of isoniazid's (INH's) mechanism of action and pharmacokinetics to optimize dosing and minimize the risk of resistance. Collaborate with other healthcare professionals to coordinate comprehensive tuberculosis management, including monitoring for adverse effects, drug interactions, and treatment outcomes. Access free multiple choice questions on this topic."}
{"id": "article-23786_3", "title": "Isoniazid -- Indications", "content": "Isoniazid (INH) is an antibiotic indicated in the first-line treatment of active Mycobacterium tuberculosis infection.", "contents": "Isoniazid -- Indications. Isoniazid (INH) is an antibiotic indicated in the first-line treatment of active Mycobacterium tuberculosis infection."}
{"id": "article-23786_4", "title": "Isoniazid -- Indications -- FDA-Approved Indications", "content": "The US Food and Drug Administration (FDA) approved INH for the following indications: Active tuberculosis\u00a0(TB) infection can present as fever, chills, night sweats, cough, hemoptysis, and weight loss. Four CDC-recommended multiple-drug regimens involve INH for drug-susceptible strains. The regimens consist of an initial phase of 2 months followed by a continuation phase of either 4 or 7 months. [1] Latent TB infection,\u00a0although rifampin-based regimens have recently replaced\u00a0INH as the primary recommendation. Rifampin-based regimens have demonstrated similar efficacy with a shorter treatment course and better completion rates. [2] Patients with HIV infection with\u00a0purified protein derivative (PPD) tuberculin skin test \u22655 mm induration and in patients with risk\u00a0factors for HIV infection with high suspicion of HIV infection. [3] Individuals with close contact with patients having TB and\u00a0PPD\u00a0\u22655 mm.", "contents": "Isoniazid -- Indications -- FDA-Approved Indications. The US Food and Drug Administration (FDA) approved INH for the following indications: Active tuberculosis\u00a0(TB) infection can present as fever, chills, night sweats, cough, hemoptysis, and weight loss. Four CDC-recommended multiple-drug regimens involve INH for drug-susceptible strains. The regimens consist of an initial phase of 2 months followed by a continuation phase of either 4 or 7 months. [1] Latent TB infection,\u00a0although rifampin-based regimens have recently replaced\u00a0INH as the primary recommendation. Rifampin-based regimens have demonstrated similar efficacy with a shorter treatment course and better completion rates. [2] Patients with HIV infection with\u00a0purified protein derivative (PPD) tuberculin skin test \u22655 mm induration and in patients with risk\u00a0factors for HIV infection with high suspicion of HIV infection. [3] Individuals with close contact with patients having TB and\u00a0PPD\u00a0\u22655 mm."}
{"id": "article-23786_5", "title": "Isoniazid -- Indications -- FDA-Approved Indications", "content": "Preventive therapy is\u00a0indicated with fibrotic pulmonary\u00a0lesions with recovered TB or in patients having pulmonary silicosis. [4] Intravenous (IV) drug users with PPD\u00a0\u226510 mm. [5]", "contents": "Isoniazid -- Indications -- FDA-Approved Indications. Preventive therapy is\u00a0indicated with fibrotic pulmonary\u00a0lesions with recovered TB or in patients having pulmonary silicosis. [4] Intravenous (IV) drug users with PPD\u00a0\u226510 mm. [5]"}
{"id": "article-23786_6", "title": "Isoniazid -- Indications -- Off-Label Use", "content": "According to the American Thoracic Society (ATS) and\u00a0the Infectious Diseases Society of America (IDSA),\u00a0INH is indicated for treating nontuberculous mycobacterial pulmonary disease. [6]", "contents": "Isoniazid -- Indications -- Off-Label Use. According to the American Thoracic Society (ATS) and\u00a0the Infectious Diseases Society of America (IDSA),\u00a0INH is indicated for treating nontuberculous mycobacterial pulmonary disease. [6]"}
{"id": "article-23786_7", "title": "Isoniazid -- Mechanism of Action", "content": "Isoniazid\u00a0has been\u00a0a significant drug in TB treatment regimens since 1952. INH is a prodrug activated by the catalase-peroxidase KatG, creating a variety of radicals and adducts that inhibit the mycobacterium's production of the mycolic acids that make up its cell wall. This activity lends\u00a0INH the ability to be a potent bactericidal agent.\u00a0The drug also appears synergistic with other species produced by KatG and other medications used to treat TB. [7] However,\u00a0mutations in the katG , inhA , kasA , and ahpC genes may cause resistance\u00a0to INH therapy. M tuberculosis resistance develops\u00a0more rapidly with\u00a0INH monotherapy. [8] [9]", "contents": "Isoniazid -- Mechanism of Action. Isoniazid\u00a0has been\u00a0a significant drug in TB treatment regimens since 1952. INH is a prodrug activated by the catalase-peroxidase KatG, creating a variety of radicals and adducts that inhibit the mycobacterium's production of the mycolic acids that make up its cell wall. This activity lends\u00a0INH the ability to be a potent bactericidal agent.\u00a0The drug also appears synergistic with other species produced by KatG and other medications used to treat TB. [7] However,\u00a0mutations in the katG , inhA , kasA , and ahpC genes may cause resistance\u00a0to INH therapy. M tuberculosis resistance develops\u00a0more rapidly with\u00a0INH monotherapy. [8] [9]"}
{"id": "article-23786_8", "title": "Isoniazid -- Mechanism of Action -- Pharmacokinetics", "content": "Absorption: Rapid and complete absorption occurs after oral or intramuscular (IM) administration. The time of peak plasma concentration is 1 to 2 hours. INH is absorbed by the small intestine and is transported by the portal system to the liver. Distribution: INH is rapidly distributed into all body tissue compartments, including cerebrospinal fluid. Plasma protein binding is\u00a010% to 15%.", "contents": "Isoniazid -- Mechanism of Action -- Pharmacokinetics. Absorption: Rapid and complete absorption occurs after oral or intramuscular (IM) administration. The time of peak plasma concentration is 1 to 2 hours. INH is absorbed by the small intestine and is transported by the portal system to the liver. Distribution: INH is rapidly distributed into all body tissue compartments, including cerebrospinal fluid. Plasma protein binding is\u00a010% to 15%."}
{"id": "article-23786_9", "title": "Isoniazid -- Mechanism of Action -- Pharmacokinetics", "content": "Metabolism: INH is inactivated via acetylation by N -acetyltransferase 2 (NAT2) in the liver and intestines.\u00a0Following the acetylation of INH, CYP2E1 oxidizes acetyl hydrazine into hepatotoxic metabolites. Rapid metabolizers can oxidize faster, which may increase the synthesis of hepatotoxins. Glutathione S-transferase (GST) protects against\u00a0hepatotoxins.\u00a0Combining GST with toxic metabolites forms\u00a0relatively non-toxic and water-soluble\u00a0metabolites that can be excreted easily. Elimination: Most of the unchanged\u00a0drug (75% to 95%) and its metabolites are excreted in the urine, while small amounts are excreted in feces and saliva. [10]", "contents": "Isoniazid -- Mechanism of Action -- Pharmacokinetics. Metabolism: INH is inactivated via acetylation by N -acetyltransferase 2 (NAT2) in the liver and intestines.\u00a0Following the acetylation of INH, CYP2E1 oxidizes acetyl hydrazine into hepatotoxic metabolites. Rapid metabolizers can oxidize faster, which may increase the synthesis of hepatotoxins. Glutathione S-transferase (GST) protects against\u00a0hepatotoxins.\u00a0Combining GST with toxic metabolites forms\u00a0relatively non-toxic and water-soluble\u00a0metabolites that can be excreted easily. Elimination: Most of the unchanged\u00a0drug (75% to 95%) and its metabolites are excreted in the urine, while small amounts are excreted in feces and saliva. [10]"}
{"id": "article-23786_10", "title": "Isoniazid -- Administration -- Available Dosage Forms and Strengths", "content": "Available\u00a0INH formulations are\u00a0tablets (100 and 300 mg), syrup (50 mg/5 mL), or IV or IM injection (100 mg/mL).\u00a0In adults, 5\u00a0mg/kg up to 300 mg daily\u00a0as a single dose daily, or 15 mg/kg up to 900 mg/d in\u00a02 to\u00a03 divided doses per week is recommended, depending on the treatment regimen chosen. Clinicians should advise the patient not to take\u00a0INH with food as the bioavailability is decreased when administered with food.", "contents": "Isoniazid -- Administration -- Available Dosage Forms and Strengths. Available\u00a0INH formulations are\u00a0tablets (100 and 300 mg), syrup (50 mg/5 mL), or IV or IM injection (100 mg/mL).\u00a0In adults, 5\u00a0mg/kg up to 300 mg daily\u00a0as a single dose daily, or 15 mg/kg up to 900 mg/d in\u00a02 to\u00a03 divided doses per week is recommended, depending on the treatment regimen chosen. Clinicians should advise the patient not to take\u00a0INH with food as the bioavailability is decreased when administered with food."}
{"id": "article-23786_11", "title": "Isoniazid -- Administration -- Available Dosage Forms and Strengths", "content": "Active TB : According to the joint guidelines by the American Thoracic Society, Centers for Disease Control and Prevention (CDC), and Infectious Diseases Society of America, the preferred regimen for\u00a0active TB infections with drug-susceptible strains consists of\u00a08 weeks of intensive\u00a0phase\u00a0treatment with INH, rifampin, pyrazinamide, and ethambutol (the RIPE regimens), followed by 18 weeks\u00a0continuation phase treatment with\u00a0INH and rifampin. Pyridoxine (vitamin B6), 25\u00a0to 50 mg/d, is administered with INH. The recommended dose of pyridoxine for patients with peripheral neuropathy is increased to 100 mg/d. [11]", "contents": "Isoniazid -- Administration -- Available Dosage Forms and Strengths. Active TB : According to the joint guidelines by the American Thoracic Society, Centers for Disease Control and Prevention (CDC), and Infectious Diseases Society of America, the preferred regimen for\u00a0active TB infections with drug-susceptible strains consists of\u00a08 weeks of intensive\u00a0phase\u00a0treatment with INH, rifampin, pyrazinamide, and ethambutol (the RIPE regimens), followed by 18 weeks\u00a0continuation phase treatment with\u00a0INH and rifampin. Pyridoxine (vitamin B6), 25\u00a0to 50 mg/d, is administered with INH. The recommended dose of pyridoxine for patients with peripheral neuropathy is increased to 100 mg/d. [11]"}
{"id": "article-23786_12", "title": "Isoniazid -- Administration -- Available Dosage Forms and Strengths", "content": "Latent TB infection: Untreated latent\u00a0TB infection has approximately\u00a0a 5%\u00a0to 10%\u00a0risk of progression to TB during\u00a0the patient's lifetime. According to the guidelines by the CDC, for the treatment of latent TB infection, the preferred regimen is\u00a03 months of\u00a0INH plus rifapentine, given weekly. An alternative regimen is\u00a09 months of INH, given daily. [12] Dosing regimens for adults and children aged 12 and older: INH and rifapentine (RPT) \u2013 given weekly for 3 months (12 doses). INH 15 mg/kg rounded up to the nearest 50 or 100 mg; 900 mg maximum RPT dosed 300 to 900 mg based on patient body weight INH and rifampin (RIF) \u2013 dosed daily for 3 months (90 doses) INH 5 mg/kg; 300 mg maximum RIF\u00a010 mg/kg; 600 mg\u00a0maximum INH monotherapy \u2013 dosed for 6 or 9 months 6-month regimens: INH 5 mg/ kg daily; maximum dose 300 mg (180 doses) INH 15 mg/kg twice weekly; maximum dose 900 mg (52 doses)", "contents": "Isoniazid -- Administration -- Available Dosage Forms and Strengths. Latent TB infection: Untreated latent\u00a0TB infection has approximately\u00a0a 5%\u00a0to 10%\u00a0risk of progression to TB during\u00a0the patient's lifetime. According to the guidelines by the CDC, for the treatment of latent TB infection, the preferred regimen is\u00a03 months of\u00a0INH plus rifapentine, given weekly. An alternative regimen is\u00a09 months of INH, given daily. [12] Dosing regimens for adults and children aged 12 and older: INH and rifapentine (RPT) \u2013 given weekly for 3 months (12 doses). INH 15 mg/kg rounded up to the nearest 50 or 100 mg; 900 mg maximum RPT dosed 300 to 900 mg based on patient body weight INH and rifampin (RIF) \u2013 dosed daily for 3 months (90 doses) INH 5 mg/kg; 300 mg maximum RIF\u00a010 mg/kg; 600 mg\u00a0maximum INH monotherapy \u2013 dosed for 6 or 9 months 6-month regimens: INH 5 mg/ kg daily; maximum dose 300 mg (180 doses) INH 15 mg/kg twice weekly; maximum dose 900 mg (52 doses)"}
{"id": "article-23786_13", "title": "Isoniazid -- Administration -- Available Dosage Forms and Strengths", "content": "9-month regimens: INH 5 mg/kg daily; maximum dose 300 mg (270 doses) INH 15 mg/kg\u00a0twice weekly; maximum dose 900 mg (76 doses)", "contents": "Isoniazid -- Administration -- Available Dosage Forms and Strengths. 9-month regimens: INH 5 mg/kg daily; maximum dose 300 mg (270 doses) INH 15 mg/kg\u00a0twice weekly; maximum dose 900 mg (76 doses)"}
{"id": "article-23786_14", "title": "Isoniazid -- Administration -- Available Dosage Forms and Strengths", "content": "Nontuberculous mycobacterial pulmonary disease: According to a joint guideline by ATS, IDSA, European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and European Respiratory Society (ERS),\u00a0patients with M kansasii infection ( rifampicin-susceptible M kansasii) should be treated with\u00a0daily administration of rifampicin, INH, and ethambutol. This regimen is associated with increased treatment success and lower relapse rates. Treatment should be continued for at least 12 months. The recommended dose of\u00a0INH is\u00a05 mg/kg up to 300 mg daily. [6]", "contents": "Isoniazid -- Administration -- Available Dosage Forms and Strengths. Nontuberculous mycobacterial pulmonary disease: According to a joint guideline by ATS, IDSA, European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and European Respiratory Society (ERS),\u00a0patients with M kansasii infection ( rifampicin-susceptible M kansasii) should be treated with\u00a0daily administration of rifampicin, INH, and ethambutol. This regimen is associated with increased treatment success and lower relapse rates. Treatment should be continued for at least 12 months. The recommended dose of\u00a0INH is\u00a05 mg/kg up to 300 mg daily. [6]"}
{"id": "article-23786_15", "title": "Isoniazid -- Administration -- Specific Patient Populations", "content": "Hepatic impairment: The manufacturer's labeling\u00a0provides no dose adjustment guidance for patients with hepatic impairment. However,\u00a0INH is metabolized in the liver, so the drug should be used cautiously in these patients. Dose adjustment may be required\u00a0for acute or chronic liver disease patients to avoid adverse effects. [13]", "contents": "Isoniazid -- Administration -- Specific Patient Populations. Hepatic impairment: The manufacturer's labeling\u00a0provides no dose adjustment guidance for patients with hepatic impairment. However,\u00a0INH is metabolized in the liver, so the drug should be used cautiously in these patients. Dose adjustment may be required\u00a0for acute or chronic liver disease patients to avoid adverse effects. [13]"}
{"id": "article-23786_16", "title": "Isoniazid -- Administration -- Specific Patient Populations", "content": "Renal impairment: No dose adjustment is\u00a0needed for patients with\u00a0renal impairment. The recommendations are to administer a full dose of\u00a0INH in patients with impaired renal function despite prolonging the drug's half-life. [13] No supplement is required for patients on peritoneal or hemodialysis.", "contents": "Isoniazid -- Administration -- Specific Patient Populations. Renal impairment: No dose adjustment is\u00a0needed for patients with\u00a0renal impairment. The recommendations are to administer a full dose of\u00a0INH in patients with impaired renal function despite prolonging the drug's half-life. [13] No supplement is required for patients on peritoneal or hemodialysis."}
{"id": "article-23786_17", "title": "Isoniazid -- Administration -- Specific Patient Populations", "content": "Pregnancy considerations: INH is considered an FDA pregnancy category C medicine. INH may cross the placental barrier. Although\u00a0INH may not cause teratogenic effects, careful monitoring of pregnant patients is recommended. Using\u00a0INH therapy to treat active TB during pregnancy is recommended as the benefit outweighs the potential risk to the fetus. Pyridoxine supplementation is a recommended intervention for these patients.", "contents": "Isoniazid -- Administration -- Specific Patient Populations. Pregnancy considerations: INH is considered an FDA pregnancy category C medicine. INH may cross the placental barrier. Although\u00a0INH may not cause teratogenic effects, careful monitoring of pregnant patients is recommended. Using\u00a0INH therapy to treat active TB during pregnancy is recommended as the benefit outweighs the potential risk to the fetus. Pyridoxine supplementation is a recommended intervention for these patients."}
{"id": "article-23786_18", "title": "Isoniazid -- Administration -- Specific Patient Populations", "content": "According to the CDC, the risk of untreated active TB disease in the pregnant woman and fetus is greater than the risks of treatment. Congenital TB can cause\u00a0bronchopneumonia and hepatosplenomegaly in neonates, with a high mortality rate. For drug-susceptible TB,\u00a09 months of\u00a0treatment with INH, rifampin, and ethambutol should be given, considering the risk-benefit evaluation. [14]", "contents": "Isoniazid -- Administration -- Specific Patient Populations. According to the CDC, the risk of untreated active TB disease in the pregnant woman and fetus is greater than the risks of treatment. Congenital TB can cause\u00a0bronchopneumonia and hepatosplenomegaly in neonates, with a high mortality rate. For drug-susceptible TB,\u00a09 months of\u00a0treatment with INH, rifampin, and ethambutol should be given, considering the risk-benefit evaluation. [14]"}
{"id": "article-23786_19", "title": "Isoniazid -- Administration -- Specific Patient Populations", "content": "Breastfeeding considerations: The manufacturer recommends not discouraging breastfeeding as the small\u00a0amount of\u00a0INH in breast milk does not produce toxicity in the infant. Pyridoxine supplementation is recommended for these patients. [15]", "contents": "Isoniazid -- Administration -- Specific Patient Populations. Breastfeeding considerations: The manufacturer recommends not discouraging breastfeeding as the small\u00a0amount of\u00a0INH in breast milk does not produce toxicity in the infant. Pyridoxine supplementation is recommended for these patients. [15]"}
{"id": "article-23786_20", "title": "Isoniazid -- Administration -- Specific Patient Populations", "content": "Pediatric patients: According to the CDC and the National Tuberculosis Controllers Association, the preferred regimen for latent TB infection is\u00a03 months of weekly\u00a0INH plus rifapentine\u00a0in children aged older than 2 years by directly observed therapy. The INH dose for children 2 to 11 years is 25 mg/kg/dose; for ages 12 and older, it is 15 mg/kg/dose. An alternative regimen is\u00a09 months of daily INH (10 to 20 mg/kg). [12] For\u00a0active TB infection,\u00a0INH is always used with other antitubercular drugs; INH is\u00a010\u00a0to 15 mg/kg daily or 20\u00a0to 30 mg/kg given twice weekly by directly observed therapy. [11]", "contents": "Isoniazid -- Administration -- Specific Patient Populations. Pediatric patients: According to the CDC and the National Tuberculosis Controllers Association, the preferred regimen for latent TB infection is\u00a03 months of weekly\u00a0INH plus rifapentine\u00a0in children aged older than 2 years by directly observed therapy. The INH dose for children 2 to 11 years is 25 mg/kg/dose; for ages 12 and older, it is 15 mg/kg/dose. An alternative regimen is\u00a09 months of daily INH (10 to 20 mg/kg). [12] For\u00a0active TB infection,\u00a0INH is always used with other antitubercular drugs; INH is\u00a010\u00a0to 15 mg/kg daily or 20\u00a0to 30 mg/kg given twice weekly by directly observed therapy. [11]"}
{"id": "article-23786_21", "title": "Isoniazid -- Administration -- Specific Patient Populations", "content": "Older patients: No\u00a0specific dose adjustment guidance is recommended in the manufacturer label for\u00a0older patients. Clinicians should exercise caution as the mortality from\u00a0TB\u00a0is\u00a0increased in\u00a0older patients. [16]", "contents": "Isoniazid -- Administration -- Specific Patient Populations. Older patients: No\u00a0specific dose adjustment guidance is recommended in the manufacturer label for\u00a0older patients. Clinicians should exercise caution as the mortality from\u00a0TB\u00a0is\u00a0increased in\u00a0older patients. [16]"}
{"id": "article-23786_22", "title": "Isoniazid -- Adverse Effects", "content": "Various adverse effects have been reported with\u00a0INH use; most are transient and low-grade.\u00a0Patients commonly experience gastrointestinal effects; some also report rash and pruritus. Peripheral neuropathy is also a commonly associated adverse event of\u00a0INH therapy, although its incidence is less than 0.2%. The risk may increase in patients with diabetes, HIV, nutritional deficiency, renal failure, alcoholism, and in women who are pregnant or breastfeeding. The mechanism of INH-induced peripheral neuropathy appears to involve interference of INH metabolites with vitamin B6 (pyridoxine) metabolism, resulting in decreased amounts of biologically active B6.\u00a0Thus, the treatment and prevention of peripheral neuropathy caused by\u00a0INH is pyridoxine supplementation during treatment. [1] [17]", "contents": "Isoniazid -- Adverse Effects. Various adverse effects have been reported with\u00a0INH use; most are transient and low-grade.\u00a0Patients commonly experience gastrointestinal effects; some also report rash and pruritus. Peripheral neuropathy is also a commonly associated adverse event of\u00a0INH therapy, although its incidence is less than 0.2%. The risk may increase in patients with diabetes, HIV, nutritional deficiency, renal failure, alcoholism, and in women who are pregnant or breastfeeding. The mechanism of INH-induced peripheral neuropathy appears to involve interference of INH metabolites with vitamin B6 (pyridoxine) metabolism, resulting in decreased amounts of biologically active B6.\u00a0Thus, the treatment and prevention of peripheral neuropathy caused by\u00a0INH is pyridoxine supplementation during treatment. [1] [17]"}
{"id": "article-23786_23", "title": "Isoniazid -- Adverse Effects", "content": "INH is also a CYP450 inhibitor (2C19: moderate,\u00a03A4: weak), potentially resulting in elevated serum concentrations of concurrent drugs such as phenytoin, carbamazepine, diazepam, and primidone. Slow acetylation may be at a higher risk for these drug-drug interactions. [18]", "contents": "Isoniazid -- Adverse Effects. INH is also a CYP450 inhibitor (2C19: moderate,\u00a03A4: weak), potentially resulting in elevated serum concentrations of concurrent drugs such as phenytoin, carbamazepine, diazepam, and primidone. Slow acetylation may be at a higher risk for these drug-drug interactions. [18]"}
{"id": "article-23786_24", "title": "Isoniazid -- Adverse Effects", "content": "Drug-induced lupus erythematosus\u00a0(DILE) has been reported in up to\u00a01% of patients taking INH. Half of the patients in these cases present with fever and pleuritis, and 30% with pericarditis.\u00a0Some experts think that slow acetylation poses an increased risk for the development of INH-induced lupus. [19] Anti-histone antibodies\u00a0are positive in most cases of drug-induced lupus. [20] Patients\u00a0on chronic hemodialysis are at increased risk of developing\u00a0severe encephalopathy. [21]", "contents": "Isoniazid -- Adverse Effects. Drug-induced lupus erythematosus\u00a0(DILE) has been reported in up to\u00a01% of patients taking INH. Half of the patients in these cases present with fever and pleuritis, and 30% with pericarditis.\u00a0Some experts think that slow acetylation poses an increased risk for the development of INH-induced lupus. [19] Anti-histone antibodies\u00a0are positive in most cases of drug-induced lupus. [20] Patients\u00a0on chronic hemodialysis are at increased risk of developing\u00a0severe encephalopathy. [21]"}
{"id": "article-23786_25", "title": "Isoniazid -- Adverse Effects -- Drug-Drug Interactions", "content": "INH is a CYP450 inhibitor, potentially resulting in elevated serum concentrations of drugs such as diazepam and primidone. Slow acetylators may be at a higher risk for these drug-drug interactions. [18] INH increases the plasma concentration of phenytoin. Therefore, to avoid phenytoin toxicity, phenytoin dose adjustment is advised. [22] Increased acetaminophen toxicity is reported with concurrent administration of INH. INH increases\u00a0the metabolism of acetaminophen, resulting in\u00a0a reduction of glutathione.\u00a0INH is also a potent inducer of CYP2E1, forming toxic metabolites and subsequent hepatotoxicity. [23] INH inhibits the metabolism of carbamazepine, resulting in increased concentration and toxicity of carbamazepine. Therefore, the dose adjustment of carbamazepine is recommended. [16] Administration of\u00a0INH with theophylline may cause\u00a0increased plasma levels of theophylline. As theophylline has a narrow therapeutic index, therapeutic drug monitoring is recommended. [24]", "contents": "Isoniazid -- Adverse Effects -- Drug-Drug Interactions. INH is a CYP450 inhibitor, potentially resulting in elevated serum concentrations of drugs such as diazepam and primidone. Slow acetylators may be at a higher risk for these drug-drug interactions. [18] INH increases the plasma concentration of phenytoin. Therefore, to avoid phenytoin toxicity, phenytoin dose adjustment is advised. [22] Increased acetaminophen toxicity is reported with concurrent administration of INH. INH increases\u00a0the metabolism of acetaminophen, resulting in\u00a0a reduction of glutathione.\u00a0INH is also a potent inducer of CYP2E1, forming toxic metabolites and subsequent hepatotoxicity. [23] INH inhibits the metabolism of carbamazepine, resulting in increased concentration and toxicity of carbamazepine. Therefore, the dose adjustment of carbamazepine is recommended. [16] Administration of\u00a0INH with theophylline may cause\u00a0increased plasma levels of theophylline. As theophylline has a narrow therapeutic index, therapeutic drug monitoring is recommended. [24]"}
{"id": "article-23786_26", "title": "Isoniazid -- Adverse Effects", "content": "Intravesical bacillus Calmette\u2013Gu\u00e9rin (BCG) vaccination is contraindicated with concurrent use of INH. [25]", "contents": "Isoniazid -- Adverse Effects. Intravesical bacillus Calmette\u2013Gu\u00e9rin (BCG) vaccination is contraindicated with concurrent use of INH. [25]"}
{"id": "article-23786_27", "title": "Isoniazid -- Contraindications -- Warnings and Precautions", "content": "INH can be administered to patients with stable liver disease, although the risk for drug accumulation and drug-induced hepatitis may increase. These patients should receive more frequent monitoring. [1] INH is contraindicated for patients with severe hypersensitivity reactions to\u00a0INH or other formulation components. [26]", "contents": "Isoniazid -- Contraindications -- Warnings and Precautions. INH can be administered to patients with stable liver disease, although the risk for drug accumulation and drug-induced hepatitis may increase. These patients should receive more frequent monitoring. [1] INH is contraindicated for patients with severe hypersensitivity reactions to\u00a0INH or other formulation components. [26]"}
{"id": "article-23786_28", "title": "Isoniazid -- Contraindications -- Box Warning", "content": "Drug-induced liver injury (DILI) has been well documented with INH. INH-associated\u00a0hepatotoxicity\u00a0usually occurs during the first\u00a03 months of treatment. Enzyme levels typically return to normal despite the continuation of the drug, but progressive liver\u00a0injury\u00a0has been reported. Risk factors associated with increased hepatotoxicity are\u00a0alcohol, preexisting chronic liver disease, IV drug abuse, and the postpartum period. [27]", "contents": "Isoniazid -- Contraindications -- Box Warning. Drug-induced liver injury (DILI) has been well documented with INH. INH-associated\u00a0hepatotoxicity\u00a0usually occurs during the first\u00a03 months of treatment. Enzyme levels typically return to normal despite the continuation of the drug, but progressive liver\u00a0injury\u00a0has been reported. Risk factors associated with increased hepatotoxicity are\u00a0alcohol, preexisting chronic liver disease, IV drug abuse, and the postpartum period. [27]"}
{"id": "article-23786_29", "title": "Isoniazid -- Monitoring", "content": "In all adults preparing to begin INH treatment, the clinician should order baseline measurements of aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin, alkaline phosphatase, serum creatinine, and platelet count. Regular monitoring of hepatic and renal function during treatment is unnecessary unless the patient has abnormal baseline levels or is at increased risk for hepatotoxicity such as alcohol misuse and hepatitis B or C infection. Serum transaminases should be measured again\u00a02 to\u00a04 weeks after treatment initiation for those patients. [1] In patients with pulmonary TB, monthly sputum specimens are necessary (until 2 consecutive negative cultures) to assess response to treatment. Patients with poor compliance history should be\u00a0monitored with a urine test. Isoscreen test checks\u00a0for\u00a0INH metabolites in the urine. [28] [29]", "contents": "Isoniazid -- Monitoring. In all adults preparing to begin INH treatment, the clinician should order baseline measurements of aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin, alkaline phosphatase, serum creatinine, and platelet count. Regular monitoring of hepatic and renal function during treatment is unnecessary unless the patient has abnormal baseline levels or is at increased risk for hepatotoxicity such as alcohol misuse and hepatitis B or C infection. Serum transaminases should be measured again\u00a02 to\u00a04 weeks after treatment initiation for those patients. [1] In patients with pulmonary TB, monthly sputum specimens are necessary (until 2 consecutive negative cultures) to assess response to treatment. Patients with poor compliance history should be\u00a0monitored with a urine test. Isoscreen test checks\u00a0for\u00a0INH metabolites in the urine. [28] [29]"}
{"id": "article-23786_30", "title": "Isoniazid -- Toxicity", "content": "The liver metabolizes INH primarily by acetylation with N -acetyl transferase 2 (NAT2). Three metabolites have implications that correlate with the liver injury associated with the drug: acetyl hydrazine (AcHz), hydrazine (Hz), and a metabolite from the bioactivation of\u00a0INH itself. Considerable variation is apparent in the acetylation rate and elimination half-life from individual to individual, which is not accounted for by dose and concentration. This appears to contribute to the risk of hepatotoxicity and the other adverse effects associated with the drug. [30]", "contents": "Isoniazid -- Toxicity. The liver metabolizes INH primarily by acetylation with N -acetyl transferase 2 (NAT2). Three metabolites have implications that correlate with the liver injury associated with the drug: acetyl hydrazine (AcHz), hydrazine (Hz), and a metabolite from the bioactivation of\u00a0INH itself. Considerable variation is apparent in the acetylation rate and elimination half-life from individual to individual, which is not accounted for by dose and concentration. This appears to contribute to the risk of hepatotoxicity and the other adverse effects associated with the drug. [30]"}
{"id": "article-23786_31", "title": "Isoniazid -- Toxicity", "content": "Mild liver injury will occur in up to 20% of patients taking INH. Clinical manifestations of hepatotoxicity include fever, fatigue, nausea, and vomiting. However, most patients experiencing INH-induced liver injury are asymptomatic. Usually,\u00a0the condition is detected only by measuring increased levels of ALT and AST, which may rise to as high as\u00a05 times the normal limit. In \u201cadaptation,\u201d the hepatic markers will return to normal in most patients with continued drug administration. About\u00a01% of patients will experience severe liver injury;\u00a0INH therapy should\u00a0cease immediately. Reintroducing\u00a0INH in these cases is contraindicated as it can cause rapid symptom onset, and fatal hepatitis during\u00a0INH treatment is associated with continued use after symptoms of hepatitis are present. [31]", "contents": "Isoniazid -- Toxicity. Mild liver injury will occur in up to 20% of patients taking INH. Clinical manifestations of hepatotoxicity include fever, fatigue, nausea, and vomiting. However, most patients experiencing INH-induced liver injury are asymptomatic. Usually,\u00a0the condition is detected only by measuring increased levels of ALT and AST, which may rise to as high as\u00a05 times the normal limit. In \u201cadaptation,\u201d the hepatic markers will return to normal in most patients with continued drug administration. About\u00a01% of patients will experience severe liver injury;\u00a0INH therapy should\u00a0cease immediately. Reintroducing\u00a0INH in these cases is contraindicated as it can cause rapid symptom onset, and fatal hepatitis during\u00a0INH treatment is associated with continued use after symptoms of hepatitis are present. [31]"}
{"id": "article-23786_32", "title": "Isoniazid -- Toxicity", "content": "INH-induced severe liver injury is generally associated with older patients and can be further exacerbated by concurrent treatment with rifampin, which induces CYP metabolism. Incidence is also higher in slow acetylators, which\u00a0correlates with higher serum levels of\u00a0INH and the AcHz metabolite. Additional risk factors include preexisting liver disease, a history of heavy alcohol use, and\u00a0patients in the postpartum period. More recently identified risk factors include polymorphisms in glutathione S-transferase, CYP2E1, TNF-\u03b1, and others. [30] Most patients recover entirely from\u00a0INH hepatotoxicity following drug discontinuation, although complete regression takes weeks. [32]", "contents": "Isoniazid -- Toxicity. INH-induced severe liver injury is generally associated with older patients and can be further exacerbated by concurrent treatment with rifampin, which induces CYP metabolism. Incidence is also higher in slow acetylators, which\u00a0correlates with higher serum levels of\u00a0INH and the AcHz metabolite. Additional risk factors include preexisting liver disease, a history of heavy alcohol use, and\u00a0patients in the postpartum period. More recently identified risk factors include polymorphisms in glutathione S-transferase, CYP2E1, TNF-\u03b1, and others. [30] Most patients recover entirely from\u00a0INH hepatotoxicity following drug discontinuation, although complete regression takes weeks. [32]"}
{"id": "article-23786_33", "title": "Isoniazid -- Toxicity", "content": "INH doses above 30 mg/kg typically cause seizures, and doses exceeding 80 mg/kg can cause death. The most commonly reported adverse reactions to INH include seizures, coma, hyperthermia, and oliguria. Additionally, acute\u00a0INH toxicity is associated with excess lactic acid produced during episodes of intense muscular rigidity.", "contents": "Isoniazid -- Toxicity. INH doses above 30 mg/kg typically cause seizures, and doses exceeding 80 mg/kg can cause death. The most commonly reported adverse reactions to INH include seizures, coma, hyperthermia, and oliguria. Additionally, acute\u00a0INH toxicity is associated with excess lactic acid produced during episodes of intense muscular rigidity."}
{"id": "article-23786_34", "title": "Isoniazid -- Toxicity", "content": "Treating\u00a0INH overdose\u00a0requires establishing\u00a0a secure airway and prompt treatment for\u00a0hypotension and seizures. Pyridoxine helps to terminate seizures and should be administered in a 1:1 ratio of grams of\u00a0INH ingested. Pyridoxine should be supplemented with\u00a0IV benzodiazepines as pyridoxine and benzodiazepines display pharmacological synergism. INH has a low volume of distribution and low plasma protein binding; hemodialysis may be considered in refractory cases. [33]", "contents": "Isoniazid -- Toxicity. Treating\u00a0INH overdose\u00a0requires establishing\u00a0a secure airway and prompt treatment for\u00a0hypotension and seizures. Pyridoxine helps to terminate seizures and should be administered in a 1:1 ratio of grams of\u00a0INH ingested. Pyridoxine should be supplemented with\u00a0IV benzodiazepines as pyridoxine and benzodiazepines display pharmacological synergism. INH has a low volume of distribution and low plasma protein binding; hemodialysis may be considered in refractory cases. [33]"}
{"id": "article-23786_35", "title": "Isoniazid -- Enhancing Healthcare Team Outcomes", "content": "Clinicians\u00a0treating TB patients with INH must be aware of the patient's baseline liver function and the hepatotoxic risks associated with INH. Although estimates of fatal hepatitis associated with INH treatment are only 0.023%, these cases correlate with continued administration despite symptoms of hepatitis during treatment. [1]", "contents": "Isoniazid -- Enhancing Healthcare Team Outcomes. Clinicians\u00a0treating TB patients with INH must be aware of the patient's baseline liver function and the hepatotoxic risks associated with INH. Although estimates of fatal hepatitis associated with INH treatment are only 0.023%, these cases correlate with continued administration despite symptoms of hepatitis during treatment. [1]"}
{"id": "article-23786_36", "title": "Isoniazid -- Enhancing Healthcare Team Outcomes", "content": "TB has widespread effects and greatly burdens individual patients and communities. Appropriate treatment is crucial for limiting the spread of TB and preventing drug resistance.\u00a0Therefore, a clinician treating TB\u00a0prescribes the appropriate treatment regimen and ensures adequate treatment adherence and completion. [1] A growing concern is INH-resistant strains of TB, and it appears that these may serve as precursors to multidrug-resistant strains.\u00a0Thus,\u00a0clinicians\u00a0should monitor patient progress to promptly detect patients not responding to INH treatment and who may harbor a resistant strain. INH-resistant strains require an altered regimen and increased efforts to prevent disease transmission. [34] [35]", "contents": "Isoniazid -- Enhancing Healthcare Team Outcomes. TB has widespread effects and greatly burdens individual patients and communities. Appropriate treatment is crucial for limiting the spread of TB and preventing drug resistance.\u00a0Therefore, a clinician treating TB\u00a0prescribes the appropriate treatment regimen and ensures adequate treatment adherence and completion. [1] A growing concern is INH-resistant strains of TB, and it appears that these may serve as precursors to multidrug-resistant strains.\u00a0Thus,\u00a0clinicians\u00a0should monitor patient progress to promptly detect patients not responding to INH treatment and who may harbor a resistant strain. INH-resistant strains require an altered regimen and increased efforts to prevent disease transmission. [34] [35]"}
{"id": "article-23786_37", "title": "Isoniazid -- Enhancing Healthcare Team Outcomes", "content": "Public health departments typically provide TB treatment. They frequently collaborate as part of an interprofessional healthcare team with other entities such as private providers, community health centers, shelters, and others to ensure the completion of treatment. The interprofessional team should use a patient-centered approach\u00a0to tailor a treatment plan specific to each patient's needs to provide the best opportunity for treatment completion. This approach often involves social workers, case managers, and medical professionals; optimal communication and coordination of services are essential.\u00a0One way\u00a0for the team to maximize adherence is through direct observation of therapy (DOT), in which healthcare professionals provide the medications directly to the patient and watch as they swallow them. This approach has become the preferred method of drug administration for TB treatment. DOT allows for early identification of nonadherence, adverse effects, or worsening of a patient's condition. [1]", "contents": "Isoniazid -- Enhancing Healthcare Team Outcomes. Public health departments typically provide TB treatment. They frequently collaborate as part of an interprofessional healthcare team with other entities such as private providers, community health centers, shelters, and others to ensure the completion of treatment. The interprofessional team should use a patient-centered approach\u00a0to tailor a treatment plan specific to each patient's needs to provide the best opportunity for treatment completion. This approach often involves social workers, case managers, and medical professionals; optimal communication and coordination of services are essential.\u00a0One way\u00a0for the team to maximize adherence is through direct observation of therapy (DOT), in which healthcare professionals provide the medications directly to the patient and watch as they swallow them. This approach has become the preferred method of drug administration for TB treatment. DOT allows for early identification of nonadherence, adverse effects, or worsening of a patient's condition. [1]"}
{"id": "article-23786_38", "title": "Isoniazid -- Enhancing Healthcare Team Outcomes", "content": "Nurses and pharmacists\u00a0are also valuable members of this interprofessional approach by verifying doses, providing patient counsel, monitoring therapeutic progress, ensuring medication compliance, and monitoring adverse events. Nurses can use the\u00a0DOT method to ensure medication compliance. Consultation from obstetricians is necessary for TB in pregnancy. Pediatricians play an essential role in the overall management of TB in children.\u00a0Infectious disease consultation is\u00a0crucial\u00a0for multidrug-resistant TB and\u00a0nontuberculous mycobacterial pulmonary disease. Interprofessional coordination and collaboration\u00a0among\u00a0physicians, advanced practice practitioners,\u00a0specialists, pharmacists, nurses, and public health professionals\u00a0can enhance patient outcomes when using\u00a0INH therapy in treating TB\u00a0infection.", "contents": "Isoniazid -- Enhancing Healthcare Team Outcomes. Nurses and pharmacists\u00a0are also valuable members of this interprofessional approach by verifying doses, providing patient counsel, monitoring therapeutic progress, ensuring medication compliance, and monitoring adverse events. Nurses can use the\u00a0DOT method to ensure medication compliance. Consultation from obstetricians is necessary for TB in pregnancy. Pediatricians play an essential role in the overall management of TB in children.\u00a0Infectious disease consultation is\u00a0crucial\u00a0for multidrug-resistant TB and\u00a0nontuberculous mycobacterial pulmonary disease. Interprofessional coordination and collaboration\u00a0among\u00a0physicians, advanced practice practitioners,\u00a0specialists, pharmacists, nurses, and public health professionals\u00a0can enhance patient outcomes when using\u00a0INH therapy in treating TB\u00a0infection."}
{"id": "article-23786_39", "title": "Isoniazid -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Isoniazid -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}